PMC:7441788 / 4210-5259 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":10,"end":15},"obj":"Body_part"},{"id":"T14","span":{"begin":913,"end":918},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T43","span":{"begin":58,"end":66},"obj":"Disease"},{"id":"T44","span":{"begin":188,"end":196},"obj":"Disease"},{"id":"T45","span":{"begin":254,"end":263},"obj":"Disease"},{"id":"T46","span":{"begin":315,"end":323},"obj":"Disease"},{"id":"T47","span":{"begin":498,"end":516},"obj":"Disease"},{"id":"T48","span":{"begin":507,"end":516},"obj":"Disease"},{"id":"T49","span":{"begin":699,"end":708},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":3,"end":15},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T33","span":{"begin":31,"end":39},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T34","span":{"begin":100,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T35","span":{"begin":297,"end":300},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T36","span":{"begin":324,"end":332},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T37","span":{"begin":359,"end":362},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T38","span":{"begin":368,"end":369},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T39","span":{"begin":387,"end":388},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T40","span":{"begin":427,"end":433},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T41","span":{"begin":646,"end":651},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T42","span":{"begin":673,"end":679},"obj":"http://purl.obolibrary.org/obo/CLO_0001751"},{"id":"T43","span":{"begin":725,"end":727},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T44","span":{"begin":761,"end":766},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T45","span":{"begin":857,"end":858},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T46","span":{"begin":906,"end":918},"obj":"http://purl.obolibrary.org/obo/CLO_0051972"},{"id":"T47","span":{"begin":906,"end":918},"obj":"http://purl.obolibrary.org/obo/CLO_0051973"},{"id":"T48","span":{"begin":906,"end":912},"obj":"http://purl.obolibrary.org/obo/CLO_0003836"},{"id":"T49","span":{"begin":934,"end":942},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T49","span":{"begin":21,"end":30},"obj":"Chemical"},{"id":"T50","span":{"begin":43,"end":45},"obj":"Chemical"},{"id":"T51","span":{"begin":146,"end":148},"obj":"Chemical"},{"id":"T52","span":{"begin":160,"end":162},"obj":"Chemical"},{"id":"T53","span":{"begin":239,"end":241},"obj":"Chemical"},{"id":"T54","span":{"begin":294,"end":296},"obj":"Chemical"},{"id":"T55","span":{"begin":356,"end":358},"obj":"Chemical"},{"id":"T56","span":{"begin":460,"end":462},"obj":"Chemical"},{"id":"T57","span":{"begin":550,"end":552},"obj":"Chemical"},{"id":"T58","span":{"begin":615,"end":617},"obj":"Chemical"},{"id":"T59","span":{"begin":742,"end":744},"obj":"Chemical"},{"id":"T60","span":{"begin":839,"end":848},"obj":"Chemical"},{"id":"T61","span":{"begin":883,"end":885},"obj":"Chemical"},{"id":"T62","span":{"begin":924,"end":933},"obj":"Chemical"},{"id":"T63","span":{"begin":946,"end":948},"obj":"Chemical"},{"id":"T64","span":{"begin":1032,"end":1034},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_90326"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_90326"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_90326"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T32","span":{"begin":43,"end":45},"obj":"Chemical"},{"id":"T33","span":{"begin":239,"end":241},"obj":"Chemical"},{"id":"T34","span":{"begin":294,"end":296},"obj":"Chemical"},{"id":"T35","span":{"begin":356,"end":358},"obj":"Chemical"},{"id":"T36","span":{"begin":460,"end":462},"obj":"Chemical"},{"id":"T37","span":{"begin":550,"end":552},"obj":"Chemical"},{"id":"T38","span":{"begin":615,"end":617},"obj":"Chemical"},{"id":"T39","span":{"begin":742,"end":744},"obj":"Chemical"},{"id":"T40","span":{"begin":883,"end":885},"obj":"Chemical"},{"id":"T41","span":{"begin":946,"end":948},"obj":"Chemical"}],"attributes":[{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T43","span":{"begin":58,"end":66},"obj":"Species"},{"id":"T44","span":{"begin":188,"end":196},"obj":"Species"},{"id":"T45","span":{"begin":315,"end":323},"obj":"Species"},{"id":"T46","span":{"begin":498,"end":506},"obj":"Species"},{"id":"T47","span":{"begin":957,"end":966},"obj":"Species"}],"attributes":[{"id":"A46","pred":"ncbi_taxonomy_id","subj":"T46","obj":"NCBItxid:694009"},{"id":"A44","pred":"ncbi_taxonomy_id","subj":"T44","obj":"NCBItxid:694009"},{"id":"A47","pred":"ncbi_taxonomy_id","subj":"T47","obj":"NCBItxid:31631"},{"id":"A45","pred":"ncbi_taxonomy_id","subj":"T45","obj":"NCBItxid:694009"},{"id":"A43","pred":"ncbi_taxonomy_id","subj":"T43","obj":"NCBItxid:694009"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T36","span":{"begin":0,"end":187},"obj":"Sentence"},{"id":"T37","span":{"begin":188,"end":269},"obj":"Sentence"},{"id":"T38","span":{"begin":270,"end":342},"obj":"Sentence"},{"id":"T39","span":{"begin":343,"end":411},"obj":"Sentence"},{"id":"T40","span":{"begin":412,"end":902},"obj":"Sentence"},{"id":"T41","span":{"begin":903,"end":1049},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"194","span":{"begin":107,"end":109},"obj":"Gene"},{"id":"195","span":{"begin":997,"end":999},"obj":"Gene"},{"id":"196","span":{"begin":1024,"end":1026},"obj":"Gene"},{"id":"197","span":{"begin":236,"end":238},"obj":"Gene"},{"id":"198","span":{"begin":124,"end":126},"obj":"Gene"},{"id":"199","span":{"begin":93,"end":95},"obj":"Gene"},{"id":"200","span":{"begin":58,"end":66},"obj":"Species"},{"id":"201","span":{"begin":188,"end":196},"obj":"Species"},{"id":"202","span":{"begin":957,"end":966},"obj":"Species"},{"id":"203","span":{"begin":315,"end":323},"obj":"Species"},{"id":"204","span":{"begin":43,"end":45},"obj":"Chemical"},{"id":"205","span":{"begin":46,"end":49},"obj":"Chemical"},{"id":"206","span":{"begin":239,"end":241},"obj":"Chemical"},{"id":"207","span":{"begin":294,"end":296},"obj":"Chemical"},{"id":"208","span":{"begin":338,"end":341},"obj":"Chemical"},{"id":"209","span":{"begin":356,"end":358},"obj":"Chemical"},{"id":"210","span":{"begin":946,"end":948},"obj":"Chemical"},{"id":"211","span":{"begin":254,"end":263},"obj":"Disease"},{"id":"212","span":{"begin":498,"end":516},"obj":"Disease"},{"id":"213","span":{"begin":699,"end":708},"obj":"Disease"},{"id":"214","span":{"begin":3,"end":9},"obj":"CellLine"},{"id":"215","span":{"begin":906,"end":912},"obj":"CellLine"}],"attributes":[{"id":"A202","pred":"pubann:denotes","subj":"202","obj":"Tax:31631"},{"id":"A194","pred":"pubann:denotes","subj":"194","obj":"Gene:56925"},{"id":"A214","pred":"pubann:denotes","subj":"214","obj":"CVCL:0574"},{"id":"A198","pred":"pubann:denotes","subj":"198","obj":"Gene:56925"},{"id":"A199","pred":"pubann:denotes","subj":"199","obj":"Gene:56925"},{"id":"A195","pred":"pubann:denotes","subj":"195","obj":"Gene:56925"},{"id":"A207","pred":"pubann:denotes","subj":"207","obj":"MESH:D002738"},{"id":"A215","pred":"pubann:denotes","subj":"215","obj":"CVCL:2514"},{"id":"A197","pred":"pubann:denotes","subj":"197","obj":"Gene:56925"},{"id":"A208","pred":"pubann:denotes","subj":"208","obj":"MESH:D006886"},{"id":"A205","pred":"pubann:denotes","subj":"205","obj":"MESH:D006886"},{"id":"A206","pred":"pubann:denotes","subj":"206","obj":"MESH:D002738"},{"id":"A209","pred":"pubann:denotes","subj":"209","obj":"MESH:D002738"},{"id":"A200","pred":"pubann:denotes","subj":"200","obj":"Tax:694009"},{"id":"A196","pred":"pubann:denotes","subj":"196","obj":"Gene:56925"},{"id":"A211","pred":"pubann:denotes","subj":"211","obj":"MESH:D007239"},{"id":"A201","pred":"pubann:denotes","subj":"201","obj":"Tax:694009"},{"id":"A204","pred":"pubann:denotes","subj":"204","obj":"MESH:D002738"},{"id":"A212","pred":"pubann:denotes","subj":"212","obj":"MESH:C000657245"},{"id":"A210","pred":"pubann:denotes","subj":"210","obj":"MESH:D002738"},{"id":"A203","pred":"pubann:denotes","subj":"203","obj":"Tax:694009"},{"id":"A213","pred":"pubann:denotes","subj":"213","obj":"MESH:D007239"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T30","span":{"begin":10,"end":15},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T31","span":{"begin":21,"end":30},"obj":"http://purl.obolibrary.org/obo/IDO_0000559"},{"id":"T32","span":{"begin":197,"end":208},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T33","span":{"begin":254,"end":263},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T34","span":{"begin":507,"end":516},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T35","span":{"begin":561,"end":572},"obj":"http://purl.obolibrary.org/obo/IDO_0000464"},{"id":"T36","span":{"begin":646,"end":651},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T37","span":{"begin":699,"end":708},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T38","span":{"begin":761,"end":766},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T39","span":{"begin":839,"end":848},"obj":"http://purl.obolibrary.org/obo/IDO_0000559"},{"id":"T40","span":{"begin":913,"end":918},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T41","span":{"begin":924,"end":933},"obj":"http://purl.obolibrary.org/obo/IDO_0000559"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T13","span":{"begin":10,"end":15},"obj":"Body_part"},{"id":"T14","span":{"begin":913,"end":918},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T37","span":{"begin":58,"end":66},"obj":"Disease"},{"id":"T38","span":{"begin":188,"end":196},"obj":"Disease"},{"id":"T39","span":{"begin":254,"end":263},"obj":"Disease"},{"id":"T40","span":{"begin":315,"end":323},"obj":"Disease"},{"id":"T41","span":{"begin":498,"end":516},"obj":"Disease"},{"id":"T42","span":{"begin":699,"end":708},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"194","span":{"begin":107,"end":109},"obj":"Gene"},{"id":"195","span":{"begin":997,"end":999},"obj":"Gene"},{"id":"196","span":{"begin":1024,"end":1026},"obj":"Gene"},{"id":"197","span":{"begin":236,"end":238},"obj":"Gene"},{"id":"198","span":{"begin":124,"end":126},"obj":"Gene"},{"id":"199","span":{"begin":93,"end":95},"obj":"Gene"},{"id":"200","span":{"begin":58,"end":66},"obj":"Species"},{"id":"201","span":{"begin":188,"end":196},"obj":"Species"},{"id":"202","span":{"begin":957,"end":966},"obj":"Species"},{"id":"203","span":{"begin":315,"end":323},"obj":"Species"},{"id":"204","span":{"begin":43,"end":45},"obj":"Chemical"},{"id":"205","span":{"begin":46,"end":49},"obj":"Chemical"},{"id":"206","span":{"begin":239,"end":241},"obj":"Chemical"},{"id":"207","span":{"begin":294,"end":296},"obj":"Chemical"},{"id":"208","span":{"begin":338,"end":341},"obj":"Chemical"},{"id":"209","span":{"begin":356,"end":358},"obj":"Chemical"},{"id":"210","span":{"begin":946,"end":948},"obj":"Chemical"},{"id":"211","span":{"begin":254,"end":263},"obj":"Disease"},{"id":"212","span":{"begin":498,"end":516},"obj":"Disease"},{"id":"213","span":{"begin":699,"end":708},"obj":"Disease"},{"id":"214","span":{"begin":3,"end":9},"obj":"CellLine"},{"id":"215","span":{"begin":906,"end":912},"obj":"CellLine"}],"attributes":[{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"Gene:56925"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"Gene:56925"},{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"Gene:56925"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"Gene:56925"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"Gene:56925"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"Gene:56925"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Tax:694009"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"Tax:694009"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"Tax:31631"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"Tax:694009"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:D002738"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:D006886"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:D002738"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D002738"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D006886"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:D002738"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:D002738"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:D007239"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:C000657245"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"MESH:D007239"},{"id":"A214","pred":"tao:has_database_id","subj":"214","obj":"CVCL:0574"},{"id":"A215","pred":"tao:has_database_id","subj":"215","obj":"CVCL:2514"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T36","span":{"begin":0,"end":187},"obj":"Sentence"},{"id":"T37","span":{"begin":188,"end":269},"obj":"Sentence"},{"id":"T38","span":{"begin":270,"end":342},"obj":"Sentence"},{"id":"T39","span":{"begin":343,"end":411},"obj":"Sentence"},{"id":"T40","span":{"begin":412,"end":902},"obj":"Sentence"},{"id":"T41","span":{"begin":903,"end":1049},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}

{"project":"2_test","denotations":[{"id":"32496926-24841269-132195657","span":{"begin":180,"end":182},"obj":"24841269"},{"id":"32496926-16640347-132195658","span":{"begin":183,"end":185},"obj":"16640347"},{"id":"32496926-15351731-132195659","span":{"begin":265,"end":267},"obj":"15351731"},{"id":"32496926-16115318-132195660","span":{"begin":898,"end":900},"obj":"16115318"},{"id":"32496926-19506054-132195661","span":{"begin":1045,"end":1047},"obj":"19506054"}],"text":"In VeroE6 cells, the antiviral activity of CQ/HCQ against SARS-CoV had an EC50 of 4.1 (±1.0) μM and 34(±5) μM, CC50 of \u003e128 μM and CC50 \u003e 100 and SI of \u003e31 and SI\u003e3, respectively [10,11]. SARS-CoV replication was inhibited by 99% at 16 μM CQ 3 days post-infection [12]. The data indicates that CQ has stronger anti-SARS-CoV activity than HCQ. In addition, CQ has both a prophylactic and a therapeutic advantage. Vincent et al. tested various concentrations of CQ (0.1–10 µM) added 20–24 h prior to SARS-CoV infection and found that 0.1, 1, and 10 µM CQ reduced infectivity by 28%, 53%, and 100%, respectively; when CQ was added immediately after virus adsorption, 0.1–1 µM and 33–100 µM reduced the infection by 50% up to 90–94%; addition of CQ 3 and 5 h after virus adsorption was still significantly effective, yet to achieve equivalent antiviral effect, a higher concentration of CQ was needed [13]. In HRT-18 cells, the antiviral activity of CQ against HCoV-OC43 had an EC50 of 0.306 (±0.091) μM, CC50 of 419.0 (±192.5) μM, and SI of 1.369 [14]."}